BD Biosciences of San Jose, Calif., and Dynomics BV of Rotterdam, the Netherlands, have reached an agreement that grants the former an exclusive worldwide license to specific intellectual property related to the flow cytometry detection of fusion proteins. Detection and identification of the proteins are important markers for diagnosing and monitoring leukemia and malignant lymphoma.